The Motley FoolT3·13d ago
PBE Invesco Biotechnology & Genome ETF
ETF 100.84 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PBE
$100.84
—
Key stats
$100.84
- 52-Week Range
- $75.35 – $104.69
- YTD
- +22.46%
- IV Rank (30D)
- 97.03
- Straddle Price
- $7.65
- P/C Vol Ratio
- 0.04
- Open
- $100.08
- Day Range
- $98.75 – $101.60
- Volume
- 21,398
- Prev Close
- $99.03
About
Invesco Biotechnology & Genome ETF (PBE) ETF
No description available.
- Exchange
- ARCX
- Inception
- 2005-06-23
- Has Options
- Yes
- Homepage
- https://www.invesco.com/us/etfs
Fund profile
holdings as of Nov 5, 2026issuer datathrough Jul 2026flows, SEC filings
- Expense ratio
- 0.59% prospectus, filed Aug 27, 2026
- Assets
- $428M shares × price, Nov 6, 2026
- Trailing yield
- 1.34% paid quarterly
- Average daily volume
- $1.7M 30 sessions
- Holdings
- 33 top 10 are 49.3%
- Listed
- Jun 23, 2005 NYSE Arca
- Last fee change
- +1 bp filed Aug 27, 2026
- Tracking difference
- -0.62 pts vs index, after fees, FY 2026
Cost44
Liquidity41
Scale60
Diversification54
Moves with. US large-cap stocks (24% of its variance, beta 0.75); Small caps over large (8% of its variance, beta 0.41); Long Treasuries (5% of its variance, beta 0.32). These factors explain 36% of its daily moves over the last year.
Stated objective. The Invesco Biotechnology & Genome ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome Intellidex Index (the Underlying Index). (from the fund's prospectus)
All 33 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs
Fund flows
through Jul 2026SEC filings- Jul 2026
- +$4.6M latest reported month
- Latest 3 months
- +$5.9M +2.1% of assets
- Latest 12 months
- −$17M −6.0% of assets
View as a table
| Month | Net flow |
|---|---|
| Jul 2026 | +$4.6M |
| Jun 2026 | +$2.9M |
| May 2026 | −$1.6M |
| Apr 2026 | +$18K |
| Mar 2026 | −$5.4M |
| Feb 2026 | −$2.5M |
| Jan 2026 | +$4.2M |
| Dec 2025 | +$834K |
| Nov 2025 | +$1.7M |
| Oct 2025 | −$722K |
| Sep 2025 | −$3.5M |
| Aug 2025 | −$17M |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | 48% | 0.55% | $3.0B | +35.7% | compare |
| BBHVanEck Biotech ETF | 43% | 0.35% | $524M | +39.4% | compare |
| IBBiShares Biotechnology ETF | 43% | 0.44% | $11.1B | +34.9% | compare |
| IBBQInvesco Nasdaq Biotechnology ETF | 41% | 0.19% | $121M | +35.2% | compare |
| FTXHFirst Trust Nasdaq Pharmaceuticals ETF | 35% | 0.60% | $1.2B | +43.9% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Nov 5, 2026issuer data- Holdings vs fair value
- +14.6% 50% under, 28% over · 100% covered
- Price / earnings
- 162.3 36% loss-making · 97% covered
- Price / book · sales
- 4.6 · 4.6 revenue growth +11.2%
- Above 200-day average
- 80% 67% above 50-day · by weight
- Short interest
- 8.6% of float, weighted · 5.6 days to cover
- Insider buying
- 0% of weight had net insider buying, 90 days; 51% net selling
- 13F holders
- +2.5% change in shares held by institutions, latest quarter
- Reporting earnings
- 5.1% of weight in 7 days; 5.1% in 14
Holdings reporting in the next 14 days · weighted implied move this week 0.38%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Jan 31, 2026 → Apr 30, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Exit | FOLDAmicus Therapeutics, Inc. | 3.90% | — | — |
| Exit | DVAXDynavax Technologies Corp. | 3.65% | — | — |
| New position | ARWRArrowhead Pharmaceuticals, Inc. | — | 3.28% | — |
| New position | CDNACareDx, Inc. | — | 3.07% | — |
| New position | TBPHTheravance Biopharma Inc. | — | 2.50% | — |
| Exit | MDGLMadrigal Pharmaceuticals, Inc. | 2.24% | — | — |
| Increase | ALNYAlnylam Pharmaceuticals, Inc. | 3.85% | 4.84% | +32.3% |
| Decrease | GILDGilead Sciences, Inc. | 5.60% | 4.62% | −14.0% |
| Increase | VCYTVeracyte, Inc. | 2.20% | 2.62% | +32.7% |
| Decrease | AMGNAmgen Inc. | 5.06% | 4.71% | −11.5% |
0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 2.3%. Full holdings and history
Under the hood
fiscal year to Apr 30, 2026SEC census- Authorized participants
- 7 active of 40 with agreements; top 3 did 79%
- Created · redeemed
- $11M · $40M over the fiscal year
- Redemptions in kind
- 100% creations 100% in kind
- Creation unit
- 10,000 shares
- Securities lending
- 12.86% of assets on loan on average; earned 14.8 bp
- Return vs index
- -0.62 pts after fees; +0.16 before; daily s.d. 0.11
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-11-05
Holdings
34
AUM
$429.7M
Provider
Invesco
Inception
2005-06-23
Exchange
ARCX
Data As Of
2026-11-05
Expense Ratio
0.59%
Dividend Yield
1.34%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-21 | 2026-09-25 | $0.0187 | CD |
| 2026-06-22 | 2026-06-26 | $0.8106 | CD |
| 2026-03-23 | 2026-03-27 | $0.0824 | CD |
| 2025-12-22 | 2025-12-26 | $0.4197 | CD |
| 2025-09-22 | 2025-09-26 | $0.2341 | CD |
| 2025-06-23 | 2025-06-27 | $0.1305 | CD |
Asset Allocation
Top Holdings
top 33 of 34 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| GILD | Gilead Sciences Inc | 5.60% | Equity (US) | US |
| BIIB | Biogen Inc | 5.49% | Equity (US) | US |
| RPRX | Royalty Pharma PLC | 5.41% | Equity (Foreign) | GB |
| REGN | Regeneron Pharmaceuticals Inc | 5.39% | Equity (US) | US |
| NTRA | Natera Inc | 5.37% | Equity (US) | US |
| AMGN | Amgen Inc | 5.17% | Equity (US) | US |
| VRTX | Vertex Pharmaceuticals Inc | 4.88% | Equity (US) | US |
| ILMN | Illumina Inc | 4.60% | Equity (US) | US |
| MRNA | Moderna Inc | 4.12% | Equity (US) | US |
| EXEL | Exelixis Inc | 3.29% | Equity (US) | US |
| VCEL | Vericel Corp | 3.25% | Equity (US) | US |
| QGEN | QIAGEN NV | 3.16% | Equity (Foreign) | NL |
| HALO | Halozyme Therapeutics Inc | 3.05% | Equity (US) | US |
| UTHR | United Therapeutics Corp | 2.96% | Equity (US) | US |
| LEGN | Legend Biotech Corp | 2.87% | Cash/Money Market | US |
| TGTX | TG Therapeutics Inc | 2.84% | Equity (US) | US |
| NBIX | Neurocrine Biosciences Inc | 2.83% | Equity (US) | US |
| NVAX | Novavax Inc | 2.81% | Equity (US) | US |
| SRPT | Sarepta Therapeutics Inc | 2.52% | Equity (US) | US |
| RGEN | Repligen Corp | 2.51% | Equity (US) | US |
| COLL | Collegium Pharmaceutical Inc | 2.48% | Equity (US) | US |
| INCY | Incyte Corp | 2.47% | Equity (US) | US |
| PTGX | Protagonist Therapeutics Inc | 2.44% | Equity (US) | US |
| PTCT | PTC Therapeutics Inc | 2.42% | Equity (US) | US |
| BMRN | BioMarin Pharmaceutical Inc | 2.30% | Equity (US) | US |
| ARDX | Ardelyx Inc | 2.15% | Equity (US) | US |
| ANAB | AnaptysBio Inc | 2.12% | Equity (US) | US |
| BCRX | BioCryst Pharmaceuticals Inc | 2.11% | Equity (US) | US |
| ACAD | ACADIA Pharmaceuticals Inc | 1.88% | Equity (US) | US |
| VCYT | Veracyte Inc | 1.48% | Equity (US) | US |
| AGPXX | Invesco Government & Agency Portfolio | 0.04% | Cash/Money Market | — |
| USD | CASH & EQUIVALENTS | 0.00% | Other | US |
| — | SECURITIES LENDING - BNYM | 0.00% | Cash/Money Market | — |
Geographic Breakdown
Non-Equity Breakdown
Invesco Biotechnology & Genome ETF ·
NPORT-P period 2026-07-31
(filed 2026-09-28)
Net assets:
$282M
· 33 total positions
· equity 100.05%
· non-equity 17.93%
Non-equity holdings
— 3 positions,
17.93% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 17.93% | $50.6M | 3 |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 7.56% | -14.98% | 6.07% | -3.44% | 3.36% | -0.58% | -0.34% |
| Feb | -5.45% | -2.22% | -5.28% | 1.10% | -3.10% | -0.93% | -2.65% |
| Mar | -3.01% | 3.82% | -2.57% | -3.83% | -3.13% | -2.66% | -1.90% |
| Apr | 1.37% | -11.35% | -0.48% | -5.51% | 0.31% | 0.02% | -2.61% |
| May | -1.68% | 0.02% | -4.82% | 0.69% | 1.53% | 5.17% | 0.15% |
| Jun | 7.27% | 1.96% | 0.60% | 1.49% | 0.78% | 8.37% | 3.41% |
| Jul | -3.32% | 3.23% | 4.02% | 8.28% | 1.46% | -0.32% | 2.23% |
| Aug | 4.02% | 0.13% | -1.06% | 2.83% | 4.44% | 7.23% | 2.93% |
| Sep | -5.55% | -3.94% | -7.96% | -0.61% | -1.02% | 0.36% | -3.12% |
| Oct | 0.59% | 5.80% | -4.69% | -1.47% | 4.46% | 7.78% | 2.08% |
| Nov | -8.05% | 3.63% | 8.61% | 1.96% | 11.57% | -0.29%* | 2.90% |
| Dec | 4.62% | -5.05% | 10.19% | -6.08% | 0.79% | -- | 0.89% |
| Total | -3.07% | -19.35% | 0.79% | -5.34% | 22.69% | 26.00% | 3.62% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $99.75
SMA 50: $97.40
SMA 200: $87.80
Current: $100.84
EMA 12: $100.63
EMA 26: $99.40
MACD: 1.2299 | Signal: -0.1483
BULLISH
ADX (14): 27.56
TREND
+DI: 33.88
−DI: 22.69
Momentum Oscillators
RSI (14): 53.97
NEUTRAL
Stoch %K: 33.94
Stoch %D: 51.93
Williams %R: -54.07
Volume & Volatility
BB Upper: $104.64
BB Lower: $94.85
NEUTRAL
OBV: 1,527,622
Vol SMA 20: 21,044
Vol ROC: 6.33%
ATR: $2.14
True Range: $2.85
HV 20: 30.7%
HV 30: 28.8%
HV 60: 25.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Here is a comprehensive stock analysis report for PBE (Invesco Biotechnology & Genome ETF) based on the provided technical indicators, options metrics, beta analysis, market data, and recent news headlines.
Executive Summary
Overall Assessment: NEUTRAL with confidence level 6/10
Key Drivers:
- Bullish MACD signal indicating a trend reversal
- RSI neutral at 58.27, suggesting no overbought or oversold conditions
Primary Risks:
- Volatility regime indicates low volatility - stock moves less than market (Stock Volatility: 0.19)
- Beta of 0.60 suggests PBE is relatively defensive compared to the broader market
Investment Thesis: PBE's recent trend reversal and neutral RSI suggest a balanced risk-reward profile. However, the low volatility regime and defensive beta may limit potential upside.
Recent News Sentiment Impact: NEUTRAL
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bearish
Support/Resistance Levels: PBE's recent high at $100.14 provides immediate resistance, while the 20-day SMA at $94.92 acts as support.
Momentum Signals:
- RSI: 58.27 - neutral
- MACD: Bullish signal above signal line (1.97 / 0.10)
- Bollinger Bands: Neutral signal with no significant band breaches
Volume Analysis: PBE's volume SMA 20 at 58340.30 indicates a relatively stable trading environment.
News & Sentiment Analysis
Recent Headlines Summary: 6 recent news headlines all have neutral sentiment, discussing PBE as a health care ETF or comparing it to other biotech ETFs (VHT vs. PBE).
Sentiment Assessment: NEUTRAL
Catalyst Identification: No specific catalysts identified in recent news headlines.
Market Narrative: PBE's market narrative remains neutral due to the lack of significant news sentiment, which does not strongly contradict technical signals.
Risk & Volatility Assessment
Beta Interpretation: PBE's beta of 0.60 indicates a relatively defensive position compared to the broader market.
Volatility Regime: Low volatility regime suggests PBE is less likely to experience large price swings.
Options Market Signals: IV rank at 92.1% (high) shows historical volatility, while the current IV at 66.7% and expected move at $4.92 indicate a relatively calm options market.
Downside Protection: Support levels at 20-day SMA ($94.92) and Bollinger Bands provide some downside protection.
Market Context & Positioning
Sector Performance: PBE's health care sector performance is neutral, moving in line with the broader market.
Institutional Activity: No significant institutional activity flags are present.
Correlation Analysis: PBE's correlation with SPY at 0.40 indicates a relatively low relationship between the two assets.
Relative Valuation: PBE trades within its historical range, indicating no significant relative undervaluation or overvaluation.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $100.14
- Support: $94.92
Breakout/Breakdown Levels:
- Breakout above $100.14 would suggest a strong bullish trend
- Breakdown below $94.92 could indicate a bearish reversal
Time-Sensitive Catalysts: No specific catalysts identified in recent news headlines.
Risk Management: Stop-loss levels should be set around $96.51, with position sizing considerations based on the expected move of $4.92.
Please let me know if you would like me to revise or expand this analysis in any way!
Generated
News
All PBE news →
Zacks Investment ResearchT3·17d ago
Zacks Investment ResearchT3·26d ago
Zacks Investment ResearchT3·27d ago
The Motley FoolT3·3mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·32mo ago
Zacks Investment ResearchT3·32mo ago
Zacks Investment ResearchT3·33mo ago
Showing 1–10 of 50
Page 1 of 5
PBE Options Activity & IV Rank
PBE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 29.4%
7-DTE IV: 31.1%
Expected Move: $7.65
7-DTE Move: $4.40
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 80
Put Volume: 3
P/C Volume: 0.037
BULLISH
Call OI: 72
Put OI: 4
P/C OI: 0.056
Total OI: 76
ATM Options Pricing
ATM Call: $4.08
ATM Put: $3.58
Call %: 4.0%
Put %: 3.5%
Chain Summary
Chain Volume: 83
Chain OI: 76
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)14.0LowNov 9
IV Rank (30 DTE)97.0HighNov 9
Straddle Price (30 DTE)$7.65Nov 9
Beta Analysis
Risk Metrics
Beta: 0.7048
Alpha: 21.51%
Correlation: 0.4769
R-Squared: 22.7%
Stock Volatility: 20.3%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
PBE Institutional Ownership (13F)
Filings for 2026-06-30 · 55 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.78K
SI % of Float
0.18%
Days to Cover
1.00
Short Vol Ratio
64.3%
Free Float
—
Float %
—
Short interest 2026-10-15 • Short volume 2026-11-09
PBE Constituent Performance
Click any bar to view the full quote for that stock.
PBE Constituents (29 of 29)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences Inc | 5.60% | $169.32 | +1.46% | -0.59% | +12.56% |
| BIIB | Biogen Inc | 5.49% | $254.87 | +2.63% | +2.35% | +11.10% |
| RPRX | Royalty Pharma PLC | 5.41% | $68.77 | +2.18% | +3.38% | +19.02% |
| REGN | Regeneron Pharmaceuticals Inc | 5.39% | $919.96 | +1.73% | -4.30% | +20.60% |
| NTRA | Natera Inc | 5.37% | $320.39 | +3.13% | -15.45% | -19.45% |
| AMGN | Amgen Inc | 5.17% | $465.23 | +1.04% | -0.05% | +11.41% |
| VRTX | Vertex Pharmaceuticals Inc | 4.88% | $550.87 | +0.69% | -0.41% | +8.65% |
| ILMN | Illumina Inc | 4.60% | $220.78 | +3.59% | -2.56% | -20.20% |
| MRNA | Moderna Inc | 4.12% | $269 | +5.83% | +21.81% | +25.85% |
| EXEL | Exelixis Inc | 3.29% | $71.74 | +3.12% | +2.30% | +19.93% |
| VCEL | Vericel Corp | 3.25% | $58.39 | +6.90% | +44.14% | +43.75% |
| QGEN | QIAGEN NV | 3.16% | $50.55 | +0.44% | +0.40% | +11.56% |
| HALO | Halozyme Therapeutics Inc | 3.05% | $102.92 | -0.69% | -20.19% | -7.35% |
| UTHR | United Therapeutics Corp | 2.96% | $582.46 | +3.64% | -2.29% | +5.88% |
| TGTX | TG Therapeutics Inc | 2.84% | $63.38 | +5.94% | +5.72% | +14.67% |
| NBIX | Neurocrine Biosciences Inc | 2.83% | $168.86 | +2.57% | +16.17% | +19.45% |
| NVAX | Novavax Inc | 2.81% | $10.89 | +1.02% | +14.27% | -13.98% |
| SRPT | Sarepta Therapeutics Inc | 2.52% | $17.24 | -3.25% | -5.90% | -1.15% |
| RGEN | Repligen Corp | 2.51% | $178.94 | +3.14% | +3.46% | +3.73% |
| COLL | Collegium Pharmaceutical Inc | 2.48% | $24.71 | +2.07% | +4.35% | +12.06% |
| INCY | Incyte Corp | 2.47% | $121.89 | +1.87% | +1.54% | +9.46% |
| PTGX | Protagonist Therapeutics Inc | 2.44% | $135.9 | +2.92% | -2.49% | -6.20% |
| PTCT | PTC Therapeutics Inc | 2.42% | $65.03 | -0.63% | +6.82% | +3.35% |
| BMRN | BioMarin Pharmaceutical Inc | 2.30% | $57.18 | +2.05% | -0.45% | +3.23% |
| ARDX | Ardelyx Inc | 2.15% | $2.93 | +1.74% | -3.30% | -9.29% |
| ANAB | AnaptysBio Inc | 2.12% | $47.97 | +3.27% | +2.26% | +4.19% |
| BCRX | BioCryst Pharmaceuticals Inc | 2.11% | $7.63 | -0.78% | -7.46% | -8.73% |
| ACAD | ACADIA Pharmaceuticals Inc | 1.88% | $16.5 | -22.28% | -19.39% | -14.99% |
| VCYT | Veracyte Inc | 1.48% | $25.92 | +7.28% | -47.10% | -41.12% |